MX339873B - Inhibidores de serina/treonina cinasa. - Google Patents

Inhibidores de serina/treonina cinasa.

Info

Publication number
MX339873B
MX339873B MX2013009877A MX2013009877A MX339873B MX 339873 B MX339873 B MX 339873B MX 2013009877 A MX2013009877 A MX 2013009877A MX 2013009877 A MX2013009877 A MX 2013009877A MX 339873 B MX339873 B MX 339873B
Authority
MX
Mexico
Prior art keywords
serine
kinase inhibitors
threonine kinase
inhibitors
compositions
Prior art date
Application number
MX2013009877A
Other languages
English (en)
Spanish (es)
Other versions
MX2013009877A (es
Inventor
Huifen Chen
Li Ren
Steven Mark Wenglowsky
James F Blake
Mark Joseph Chicarelli
Jason Demeese
Rustam Garrey
John J Guadino
Robert J Kaus
Gabrielle R Kolakowski
Allison L Marlow
Peter J Mohr
Jacob Schwarz
Christopher S Siedem
Allen A Thomas
Eli Wallace
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013009877A publication Critical patent/MX2013009877A/es
Publication of MX339873B publication Critical patent/MX339873B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2013009877A 2011-02-28 2012-02-28 Inhibidores de serina/treonina cinasa. MX339873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161447587P 2011-02-28 2011-02-28
PCT/US2012/027009 WO2012118850A1 (en) 2011-02-28 2012-02-28 Serine/threonine kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2013009877A MX2013009877A (es) 2014-02-11
MX339873B true MX339873B (es) 2016-06-15

Family

ID=45852719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009877A MX339873B (es) 2011-02-28 2012-02-28 Inhibidores de serina/treonina cinasa.

Country Status (11)

Country Link
US (1) US9133187B2 (enExample)
EP (1) EP2681215B1 (enExample)
JP (1) JP6085866B2 (enExample)
KR (1) KR101961500B1 (enExample)
CN (1) CN103635472B (enExample)
BR (1) BR112013021896A2 (enExample)
CA (1) CA2828478C (enExample)
ES (1) ES2543050T3 (enExample)
MX (1) MX339873B (enExample)
RU (1) RU2013143839A (enExample)
WO (1) WO2012118850A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101961500B1 (ko) 2011-02-28 2019-03-22 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제
CA2839699A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
JP6089045B2 (ja) * 2011-12-27 2017-03-01 バイオ−ファーム ソリューションズ カンパニー リミテッド 痛みの緩和または治療に使用するためのフェニルカルバメート化合物
UA116774C2 (uk) 2012-03-01 2018-05-10 Еррей Біофарма Інк. Інгібітори серин/треонінкінази
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
KR20150047597A (ko) 2012-08-27 2015-05-04 어레이 바이오파마 인크. 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제
BR112015005982A2 (pt) 2012-09-19 2017-07-04 Novartis Ag di-hidropirrolidino-pirimidinas como inibidores de quinase
RU2015114936A (ru) 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
JPWO2015012328A1 (ja) * 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
JP6449293B2 (ja) 2013-12-06 2019-01-09 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
JP6642942B2 (ja) 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
MX382339B (es) * 2016-05-18 2025-03-13 Mirati Therapeutics Inc Inhibidores g12c de kras.
CN111373055B (zh) 2017-09-08 2024-07-23 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
ES2967094T3 (es) 2017-09-29 2024-04-26 Mitsubishi Tanabe Pharma Corp Compuesto de pirrolidina ópticamente activo y procedimiento de producción del mismo
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2020192750A1 (zh) 2019-03-28 2020-10-01 江苏恒瑞医药股份有限公司 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
BR112021018924A2 (pt) 2019-03-29 2022-02-01 Jiangsu Hengrui Medicine Co Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
CN113825757B (zh) 2019-05-24 2023-10-20 江苏恒瑞医药股份有限公司 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
WO2020238791A1 (zh) * 2019-05-24 2020-12-03 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN111170929A (zh) * 2019-12-12 2020-05-19 北京达因高科儿童药物研究院有限公司 一种由末端烯烃制备β-氨基醇的方法
ES3033417T3 (en) * 2020-09-25 2025-08-04 Janssen Pharmaceutica Nv Cyclin-dependent kinase 7 (cdk7) non-covalent inhibitors
CN116437915B (zh) 2020-09-29 2025-03-18 江苏恒瑞医药股份有限公司 一种吡咯并杂环类衍生物的晶型及其制备方法
CN115040522B (zh) * 2022-06-30 2024-02-06 牡丹江医学院 一种用于治疗肺癌的药物及其制备方法
KR20250091232A (ko) * 2022-10-25 2025-06-20 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피페리디노피리미딘계 유도체, 이의 제조 방법 및 이의 의학적 응용
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3
TW202535869A (zh) * 2023-10-23 2025-09-16 大陸商上海拓界生物醫藥科技有限公司 一種含有噻唑基的哌啶并嘧啶類衍生物、其製備方法及其醫藥上的應用
WO2025223512A1 (zh) * 2024-04-24 2025-10-30 江苏恒瑞医药股份有限公司 一种二氢吡啶并嘧啶衍生物的可药用盐、结晶形式及用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705502A (en) 1993-10-01 1998-01-06 Novartis Corporation Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003099808A1 (en) 2002-05-21 2003-12-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
ATE451369T1 (de) 2002-07-15 2009-12-15 Merck & Co Inc Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
WO2007028022A2 (en) * 2005-09-01 2007-03-08 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
US20100292205A1 (en) 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
US8063066B2 (en) * 2007-03-19 2011-11-22 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
JP5611826B2 (ja) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
WO2009061761A2 (en) 2007-11-06 2009-05-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic amines
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
WO2010077275A1 (en) 2008-12-08 2010-07-08 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
KR101961500B1 (ko) 2011-02-28 2019-03-22 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
UA116774C2 (uk) 2012-03-01 2018-05-10 Еррей Біофарма Інк. Інгібітори серин/треонінкінази
KR20150047597A (ko) 2012-08-27 2015-05-04 어레이 바이오파마 인크. 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제

Also Published As

Publication number Publication date
US9133187B2 (en) 2015-09-15
CN103635472A (zh) 2014-03-12
KR20140014190A (ko) 2014-02-05
EP2681215B1 (en) 2015-04-22
CA2828478A1 (en) 2012-09-07
MX2013009877A (es) 2014-02-11
ES2543050T3 (es) 2015-08-14
RU2013143839A (ru) 2015-04-10
JP6085866B2 (ja) 2017-03-01
JP2014506930A (ja) 2014-03-20
WO2012118850A1 (en) 2012-09-07
CN103635472B (zh) 2018-01-12
CA2828478C (en) 2019-12-31
BR112013021896A2 (pt) 2016-11-08
EP2681215A1 (en) 2014-01-08
US20130338140A1 (en) 2013-12-19
KR101961500B1 (ko) 2019-03-22

Similar Documents

Publication Publication Date Title
MX339873B (es) Inhibidores de serina/treonina cinasa.
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
WO2014100764A3 (en) Methods of inhibiting prmt5
PH12017502141A1 (en) Compounds and their methods of use
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EP2670749A1 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
WO2012158843A3 (en) Kinase inhibitors
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
WO2013003298A3 (en) Inhibitors of pde10
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
PH12016501071B1 (en) Serine/threonine kinase inhibitors
NZ711192A (en) Process for making benzoxazepin compounds
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
EP2882744B8 (en) Process for the preparation of c-fms kinase inhibitors
GB201107985D0 (en) Process
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
EP2648728A4 (en) JANUS KINASE-2 (JAK2) INHIBITOR FOR THE TREATMENT OF LUPUS
WO2013013238A3 (en) Compounds and related compositions and methods of use
MX2014007398A (es) Derivado de 2,4-diamina-pirimidina como inhibidores de serina/treonina quinasa.
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
HK1175650A1 (zh) 化合物

Legal Events

Date Code Title Description
FG Grant or registration